RESUMO
OBJECTIVE: To compare the treatment outcome and prognosis of the newly-treated myc+/bcl-2+/bcl-6- lymphoma (bcl-6- double-expression lymphoma, bcl-6- DEL) and myc+/bcl-2+/bcl-6+ co-expression lymphoma (bcl-6+ double-expression lymphoma, bcl-6+ DEL) patients treated by R-CHOP. METHODS: 152 double-expression lymphoma patients (myc+/bcl-2+) treated in the Oncology Department of the First Affiliated Hospital of Zhengzhou University from September 2016 to June 2020 were selected. The short-term efficacy and long-term survival between the patients with bcl-6- DEL and bcl-6+ DEL was analyzed. RESULTS: The median age of 152 DEL patients was 60.5 years old (15-87 years old). 85 patients (55.9%) were Ann Arbor stage III/IV. There was no significant difference in clinical data between the patients in the two groups. Multivariate Cox regression analysis showed that bcl-6 expression, ECOG score, and stage were the independent prognostic factors for the entire group of DEL patients. There was no statistical difference in ORR between the patients in the two groups (χ2=0.749, P=0.387). Kaplan-Meier survival analysis showed that PFS and OS of the bcl-6+ DEL group were significantly higher than those in bcl-6- DEL group (PFS: χ2=6.095, P=0.014; OS: χ2=5.133, P=0.023). CONCLUSION: bcl-6+ is a good prognostic factor for DEL. The long-term curative effect of newly-treated bcl-6+ DEL patients treated by R-CHOP regimen is higher than those with bcl-6- DEL patients.